Skip to main content

Advertisement

SpringerLink
Log in

Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Pancreatic cancer (PC) has a high mortality rate because it is usually diagnosed late. Glycosylation of proteins is known to change in tumor cells during the development of PC. The objectives of this study were to identify and validate the diagnostic value of novel biomarkers based on N-glycomic profiling for PC. In total, 217 individuals including subjects with PC, pancreatitis, and healthy controls were divided randomly into a training group (n = 164) and validation groups (n = 53). Serum N-glycomic profiling was analyzed by DSA–FACE. The diagnostic model was constructed based on N-glycan markers with logistic stepwise regression. The diagnostic performance of the model was assessed further in validation cohort. The level of total core fucose residues was increased significantly in PC. Two diagnostic models designated GlycoPCtest and PCmodel (combining GlycoPCtest and CA19-9) were constructed to differentiate PC from normal. The area under the receiver operating characteristic curve (AUC) of PCmodel was higher than that of CA19-9 (0.925 vs. 0.878). The diagnostic models based on N-glycans are new, valuable, noninvasive alternatives for identifying PC. The diagnostic efficacy is improved by combined GlycoPCtest and CA19-9 for the discrimination of patients with PC from healthy controls.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  PubMed  Google Scholar 

  2. Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318–48.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ueno H, Kosuge T, Matsuyama Y, et al. A randomized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164–9.

    Article  CAS  PubMed  Google Scholar 

  5. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15–22.

    Article  PubMed  Google Scholar 

  6. Haridas D, Chakraborty S, Ponnusamy MP, et al. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One. 2011;6:e26839.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ravindranath MH, Yesowitch P, Sumobay C, et al. Glycoimmunomics of human cancer: current concepts and future perspectives. Future Oncol. 2007;3:201–14.

    Article  CAS  PubMed  Google Scholar 

  8. Arnold JN, Saldova R, Hamid UM, et al. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics. 2008;8:3284–93.

    Article  CAS  PubMed  Google Scholar 

  9. Lech G, Slotwinski R, Krasnodebski IW. The role of tumor markers and biomarkers in colorectal cancer. Neoplasma. 2014;61:1–8.

    Article  CAS  PubMed  Google Scholar 

  10. Ruhaak LR, Miyamoto S, Lebrilla CB. Developments in the identification of glycan biomarkers for the detection of cancer. Mol Cell Proteomics. 2013;12:846–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mechref Y, Hu Y, Garcia A, et al. Defining putative glycan cancer biomarkers by MS. Bioanalysis. 2012;4:2457–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hua S, An HJ. Glycoscience aids in biomarker discovery. BMB Rep. 2012;45:323–30.

    Article  CAS  PubMed  Google Scholar 

  13. Callewaert N, Van Vlierberghe H, Van Hecke A, et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer based total serum protein glycomics. Nat Med. 2004;10:429–34.

    Article  CAS  PubMed  Google Scholar 

  14. Lebrilla CB, An HJ. The prospects of glycan biomarkers for the diagnosis of diseases. Mol BioSyst. 2009;5:17–20.

    Article  CAS  PubMed  Google Scholar 

  15. Wong D, Ko AH, Hwang J, et al. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008;37:269–74.

    Article  PubMed  Google Scholar 

  16. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15–22.

    Article  PubMed  Google Scholar 

  17. Singh S, Tang SJ, Sreenarasimhaiah J, et al. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci. 2011;56:2491–6.

    Article  CAS  PubMed  Google Scholar 

  18. Hamada S, Shimosegawa T. Biomarkers of pancreatic cancer. Pancreatology. 2011;11:14–9.

    Article  CAS  PubMed  Google Scholar 

  19. Smith RA, Bosonnet L, Ghaneh P, Neoptolemos JP, et al. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg. 2008;25:226–32.

    Article  CAS  PubMed  Google Scholar 

  20. Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol. 2013;34:3279–92.

    Article  CAS  PubMed  Google Scholar 

  21. Shaw VE, Lane B, Jenkinson C, Cox T, et al. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Cancer. 2014;13:114.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Pilobello KT, Mahal LK. Lectin microarrays for glycoprotein analysis. Methods Mol Biol. 2007;385:193–203.

    Article  CAS  PubMed  Google Scholar 

  23. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006;126:855–67.

    Article  CAS  PubMed  Google Scholar 

  24. Häuselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. Front Oncol. 2014;4:28.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Wang J, Zhou C, Zhang W, et al. An integrative strategy for quantitative analysis of the N-glycoproteome in complex biological samples. Proteome Sci. 2014;12:4.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Moriwaki K, Miyoshi E. Fucosylation and gastrointestinal cancer. World J Hepatol. 2010;2:151–61.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Pochechueva T, Jacob F, Fedier A, et al. Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches. Metabolites. 2012;2:913–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ono M, Hakomori S. Glycosylation defining cancer cell motility and invasiveness. Glycoconj J. 2004;20:71–8.

    Article  CAS  PubMed  Google Scholar 

  29. Fang M, Zhao YP, Zhou FG, et al. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma. Int J Cancer. 2010;127:148–59.

    Article  CAS  PubMed  Google Scholar 

  30. Zhao YP, Ruan CP, Wang H, et al. Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling. Cancer. 2012;118:639–50.

    Article  CAS  PubMed  Google Scholar 

  31. Zhao YP, Xu XY, Fang M, et al. Decreased core-fucosylation contributes to malignancy in gastric cancer. PLoS One. 2014;9:e94536.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Bloomston M, Bekaii-Saab TS, Kosuri K, et al. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection. Pancreas. 2006;33:246–9.

    Article  CAS  PubMed  Google Scholar 

  33. Vestergaard EM, Hein HO, Meyer H, et al. Reference values and biological variation for tumor marker CA19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem. 1999;45:54–61.

    CAS  PubMed  Google Scholar 

  34. Salvini R, Bardoni A, Valli M, et al. Beta 1,3-Galactosyltransferase beta 3Gal-T5 acts on the GlcNAcbeta 1–>3Galbeta 1–>4GlcNAcbeta 1–>R sugar chains of carcinoembryonic antigen and other N-linked glycoproteins and is down-regulated in colon adenocarcinomas. J Biol Chem. 2001;276:3564–73.

    Article  CAS  PubMed  Google Scholar 

  35. Liao WC, Tu YK, Wu MS, et al. Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis. BMJ. 2015;349:g7371.

    Article  PubMed  Google Scholar 

  36. Tonack S, Jenkinson C, Cox T, et al. iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. Br J Cancer. 2013;108:1846–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by the Science and Technology Commission of Shanghai Municipality (Grants No. 11JC1416400) and by the National Natural Science Foundation of China (Grants No. 81201697 and No. 81101639).

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Rd, Shanghai, 200438, China

    Yun-Peng Zhao, Ping-Ting Zhou, Meng Fang, Meng-Meng Wang, Yue-Peng Yin & Chun-Fang Gao

  2. Department of Surgery, Changhai Hospital, Second Military Medical University, 116 Changhai Rd, Shanghai, 200438, China

    Wei-Ping Ji & Gang Jin

  3. Department of Laboratory Medicine, Changzheng Hospital, Second Military Medical University, Shanghai, China

    Hao Wang

Authors
  1. Yun-Peng Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ping-Ting Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei-Ping Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meng Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Meng-Meng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yue-Peng Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gang Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chun-Fang Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Gang Jin or Chun-Fang Gao.

Ethics declarations

Conflict of interest

None.

Additional information

Yun-Peng Zhao, Ping-Ting Zhou, and Wei-Ping Ji are the co-first authors.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 207 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, YP., Zhou, PT., Ji, WP. et al. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer. Clin Exp Med 17, 9–18 (2017). https://doi.org/10.1007/s10238-015-0401-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-015-0401-2

Keywords

Search

Navigation